Redeye Feed

2026-02-26 15:29:00 OncoZenge (Q4 review): Final preparations ahead of phase III

2026-02-26 11:24:00 Better Collective (Q4 Initial take): Solid Q4 and guidance in line with expectations

2026-02-26 11:23:00 GiG Software (Q4 Review): Strong growth outlook remains, but from a lower base

2026-02-26 11:22:00 Medivir (Q4 review): Directed Issue Unlocked Significant Value

2026-02-26 09:45:00 Fluoguide (Q4 Initial take): Key milestones to drive value in 2026

2026-02-26 09:43:00 Lipum (Q4 Reviev): Approaching merger completion

2026-02-26 09:42:00 BONESUPPORT (Q4 Review): Entering a 2026 full of inflexion points

2026-02-26 09:40:00 Gentoo Media (Q4 Review): Back to growth

2026-02-26 09:39:00 Waystream (Q4 Review): Market share gains in a subdued market

2026-02-24 14:18:00 Gentoo Media (Initial take): Solid Q4 in line with preliminary results

2026-02-24 14:16:00 Starbreeze (Q4 Review): Cost adjustments underway

2026-02-24 10:31:00 Cheffelo (Q4 Review): Execution served on a quarterly basis

2026-02-24 10:30:00 Cantargia (Q4 Review): New Developments in PDAC

2026-02-24 10:28:00 Siljansvik (Q4 Review): The value creation process continues

2026-02-24 10:27:00 BioArctic (Q4 review): High quality, high expectations

2026-02-23 11:44:00 Xbrane Biopharma (Q4 review): Challenging outlook

2026-02-23 11:33:00 Teneo AI: Company Update

2026-02-23 10:17:00 Absolent: Growth Resumed

2026-02-23 10:15:00 Navigo (Q4 review): Strong year-end momentum supports 2026 outlook

2026-02-23 10:14:00 CLS Q4 (Review): Low sales due to alignment discussions with ClearPoint Neuro

2026-02-23 10:13:00 Paxman: CPT-III codes for Paxman’s CIPN device

2026-02-23 10:12:00 InfraCom (Q4 Review): Margin reset; acquisition optionality reopens

2026-02-23 10:11:00 Freemelt (Q4 Review): Business activity remains high

2026-02-23 10:10:00 Formpipe (Q4 review): Profitability secured, growth in focus for 2026

2026-02-23 10:09:00 Siljansvik (Q4 Initial Take): Higher dividend and increased market-based NAV

2026-02-20 16:26:00 Initiator Pharma (Q4 Review): Dosing underway in phase IIa study

2026-02-20 13:54:00 Oncopeptides (Q4 Update): Political Risk in Spain and a Slower Germany

2026-02-20 13:53:00 Surgical Science (Q4 Review): Must continue to regain confidence

2026-02-20 13:52:00 BICO (Q4 review): Improving outlook and trades at <1x sales

2026-02-20 13:51:00 G5 Entertainment (Q4 Review): Growth turnaround stalled

2026-02-20 13:50:00 OEM International (Q4 review): Soft end to 2025, but M&A starting to contribute

2026-02-20 13:48:00 Fable Media Group (Q4 Review): Calm Before the Kickoff

2026-02-19 13:41:00 SSH Communications Security (Q4 interview): Redeye speaks with CEO Rami Raulas

2026-02-19 13:39:00 ExpreS2ion Biotech (Q4 Review): Progress on multiple fronts

2026-02-19 13:38:00 Moberg Pharma (Q4 Review): Solid ending to a breakthrough year

2026-02-19 09:43:00 Scandinavian ChemoTech (Q4 Review): Seasonal softness, intact growth case

2026-02-19 09:41:00 EG7 (Q4 Review): Balance sheet clean-up supports valuation improvement

2026-02-19 09:40:00 Momentum Group (Q4 review): Temporary hiccup

2026-02-19 09:39:00 SSH (Q4 Review): 2026 – The Year for Growth

2026-02-19 09:38:00 Modelon (Q4 Review): Operational leverage in place for the 2026 growth pivot

2026-02-19 09:36:00 Isofol Medical (Q4 Review): Translational year ahead

2026-02-19 09:35:00 Senzime (Q4 Review): Solid report and a positive 2026 outlook

2026-02-19 09:34:00 Avensia (Q4 review): Challenging market dynamics continue – opportunities in B2B, back-end, and AI

2026-02-18 12:31:00 Cinclus Pharma (Q4 Review): Phase III advancing on time

2026-02-18 11:30:00 Senzime (Q4 Initial take): Sales spot on to our estimate

2026-02-18 11:28:00 Boreo (Q4 review): Solid execution, optimistic outlook

2026-02-18 11:27:00 Relais (Q4 review): Stable performance despite challenges

2026-02-18 11:26:00 Truecaller (Q4 Review): Transformative pivot amid advertising headwinds

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Redeye

Prenumeration

Vem äger bolaget?

Redeye

Prenumeration

Vem äger bolaget?

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden